Viking Therapeutics VKTX Stock
Viking Therapeutics Price Chart
Viking Therapeutics VKTX Financial and Trading Overview
| Viking Therapeutics stock price | 27.58 USD |
| Previous Close | 28.44 USD |
| Open | 27.76 USD |
| Bid | 26.37 USD x 100 |
| Ask | 29.4 USD x 100 |
| Day's Range | 27.5 - 28.56 USD |
| 52 Week Range | 23.82 - 43.1 USD |
| Volume | 2.19M USD |
| Avg. Volume | 5.07M USD |
| Market Cap | 3.52B USD |
| Beta (5Y Monthly) | 0.753 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -5.42 USD |
| Forward Dividend & Yield | N/A (0%) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 95.32 USD |
VKTX Valuation Measures
| Enterprise Value | 2.92B USD |
| Trailing P/E | N/A |
| Forward P/E | -5.2951093 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 5.9748697 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | N/A |
Trading Information
Viking Therapeutics Stock Price History
| Beta (5Y Monthly) | 0.753 |
| 52-Week Change | -27.076% |
| S&P500 52-Week Change | 13.08% |
| 52 Week High | 43.1 USD |
| 52 Week Low | 23.82 USD |
| 50-Day Moving Average | 29.54 USD |
| 200-Day Moving Average | 32.19 USD |
VKTX Share Statistics
| Avg. Volume (3 month) | 5.07M USD |
| Avg. Daily Volume (10-Days) | 4.2M USD |
| Shares Outstanding | 127.52M |
| Float | 124.6M |
| Short Ratio | 4.53 |
| % Held by Insiders | 2.83% |
| % Held by Institutions | 63.54% |
| Shares Short | 24.16M |
| Short % of Float | 19.92% |
| Short % of Shares Outstanding | 18.94% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | N/A |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | September 30, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -47.22% |
| Return on Equity (ttm) | -96.37% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | N/A |
| Net Income Avi to Common (ttm) | -627195008 USD |
| Diluted EPS (ttm) | -5.42 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 959.81M USD |
| Total Cash Per Share (mrq) | 7.53 USD |
| Total Debt (mrq) | 254.69M USD |
| Total Debt/Equity (mrq) | 43.27 USD |
| Current Ratio (mrq) | 7.267 |
| Book Value Per Share (mrq) | 4.616 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -462632000 USD |
| Levered Free Cash Flow (ttm) | -237779504 USD |
Profile of Viking Therapeutics
| Country | United States |
| State | CA |
| City | San Diego |
| Address | 9920 Pacific Heights Boulevard |
| ZIP | 92121 |
| Phone | 858 704 4660 |
| Website | https://www.vikingtherapeutics.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 74 |
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. The company develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, which is in Phase II clinical trials for metabolic disorders and anemia; VK2735, a novel dual agonist of the glucagon-like peptide 1, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
Q&A For Viking Therapeutics Stock
What is a current VKTX stock price?
Viking Therapeutics VKTX stock price today per share is 27.58 USD.
How to purchase Viking Therapeutics stock?
You can buy VKTX shares on the Tech Market Small exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Viking Therapeutics?
The stock symbol or ticker of Viking Therapeutics is VKTX.
Which industry does the Viking Therapeutics company belong to?
The Viking Therapeutics industry is Biotechnology.
How many shares does Viking Therapeutics have in circulation?
The max supply of Viking Therapeutics shares is 127.52M.
What is Viking Therapeutics Price to Earnings Ratio (PE Ratio)?
Viking Therapeutics PE Ratio is now.
What was Viking Therapeutics earnings per share over the trailing 12 months (TTM)?
Viking Therapeutics EPS is -5.42 USD over the trailing 12 months.
Which sector does the Viking Therapeutics company belong to?
The Viking Therapeutics sector is Healthcare.
Viking Therapeutics VKTX included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
|
|
|
- | |||||
US Tech Composite
IXIC
US
|
25366.09 USD — |
-0.39
|
8.86B USD — | 25068.28 USD — | 25597.23 USD — | — - | 8.86B USD — |
|
US Tech Capital Market Composite
RCMP
US
|
114.29 USD — |
-2.39
|
— — | 113.87 USD — | 116.2 USD — | — - | — — |
|
US Tech Health Care
IXHC
US
|
1372.96 USD — |
-1.99
|
— — | 1372.67 USD — | 1394.6 USD — | — - | — — |
|
US Tech Composite Total Return
XCMP
US
|
31344.11 USD — |
-0.38
|
— — | 30976.16 USD — | 31629.69 USD — | — - | — — |
